This site is intended for healthcare professionals
COMT inhibition in Parkinson’s Disease Learning Zone


Read time: 70 mins
There are no disease-modifying treatments for the progressive neurodegenerative condition Parkinson’s disease (PD).

Current medical management largely focuses on controlling the classic motor symptoms of bradykinesia, tremor, rigidity and postural instability1,2

Dopaminergic pharmacotherapies designed to restore depleted dopamine in the substantia nigra pars compacta are the mainstay of PD treatment and include addition of dopamine precursors, direct activation of dopamine receptors, and prevention of the endogenous dopamine breakdown2.

Register free for full access to